Just very briefly, I'm really excited about your question of what we can do to better understand the etiology of Parkinson's treatment and progression. We're currently just about to start a two-year study, which will be led by one of my doctoral students. We're going to look at Parkinson's patients throughout the province of Ontario—what medications they take, how effective those medications are, and whether there are any adverse reactions to those medications.
With a population of 12 million people we have retrospective data on going back some 15 years, we'll be able to get a really good handle on the factors affecting the onset, the progression of the disease in a large population, and particularly looking at the effectiveness of the medications the patients are taking.
A second part of the same study will be a parallel analysis of a similar data set from the United States. That is actually larger. We have data from 500 U.S. health care institutions, representing over 35 million patients' electronic health records. We'll do two analyses, one based on a large Canadian data set from Ontario and one based on nationally representative U.S. data sets. When those results are in, I think they'll be tremendously useful to answer some of the questions you're posing this morning.